CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel immune modulatory oligonucleotides (IMO), chemical modifications of IMOs, and methods of inducing an immune response through administering such compounds.
